Core Viewpoint - The company Boan Biotechnology (06955) has announced that its self-developed drug BA6101 has received approval for market launch in Bolivia, which is a biosimilar to the reference drug Prolia® used for osteoporosis treatment [1][6]. Group 1: Stock Performance - Boan Biotechnology's stock price increased by 6.07%, currently trading at 9.96 HKD, with a trading volume of 54.81 million HKD [1][6]. Group 2: Product Approval - The Bolivian National Medicines and Health Technologies Agency (AGEMED) has approved the injection of BA6101 (60mg) for market launch [1][6]. - BA6101 is a biosimilar to Prolia®, which is widely used globally for the treatment of osteoporosis, and it shares the same indications as the reference drug [1][6]. Group 3: Global Development Strategy - BA6101 is developed based on the company's global research and development strategy, with plans for commercialization in multiple countries and regions [1][6]. - The company is currently in the approval process for BA6101's marketing authorization in the UK and plans to submit applications in Europe, the United States, Japan, and other regions [1][6].